Mihaela Lorger
Has grant
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Elucidating type 1 conventional dendritic cell-dependent anti-tumour immune responses in brain metastases
Open Date: 2024-02-01
Close Date: 2027-07-31
Grant: Close
Molecular determinants of resistance to immune checkpoint blockade in melanoma brain metastases
Open Date: 2022-10-01
Close Date: 2026-09-30
Grant: Close
Psoriasis and eczema modulate susceptibility to arbovirus infection
Open Date: 2020-11-01
Close Date: 2024-07-31
Grant: Close
Harnessing T cells to target brain metastasis.
Open Date: 2019-10-01
Close Date: 2023-06-30
Grant: Close
Mechanisms underlying inhibition of melanoma brain metastases upon immune checkpoint targeting
Open Date: 2019-01-01
Close Date: 2023-05-31
Articles (3)
Priego and colleagues identify a secreted glycoprotein TIMP1, expressed downstream of the transcription factor STAT3, in a subpopulation of STAT3+ reactive astrocytes as a mediator of immunosuppression in late-stage brain metastases. The STAT3 inhibitor silibinin enhances the preclinical efficacy of the combined PD-1/CTLA4 immune checkpoint blockade, providing a rationale to translate the combination therapy into clinical use for this underserved patient group with poor prognosis. See related article by Priego et al., p. 179
Year:
2025
The role of endothelial cells in promoting cancer cell extravasation to the brain during the interaction of cancer cells with the vasculature is not well characterised. We show that brain endothelial cells activate EGFR signalling in triple-negative breast cancer cells with propensity to metastasise to the brain. This activation is dependent on soluble factors secreted by brain endothelial cells, and occurs via the RAC1 GEF DOCK4, which is required for breast cancer cell extravasation to the brain in vivo. Knockdown of DOCK4 inhibits breast cancer cell entrance to the brain without affecting cancer cell survival or growth. Defective extravasation is associated with loss of elongated morphology preceding intercalation into brain endothelium. We also show that brain endothelial cells promote paracrine stimulation of mesenchymal-like morphology of breast cancer cells via DOCK4, DOCK9, RAC1 and CDC42. This stimulation is accompanied by EGFR activation necessary for brain metastatic breast cancer cell elongation which can be reversed by the EGFR inhibitor Afatinib. Our findings suggest that brain endothelial cells promote metastasis through activation of cell signalling that renders breast cancer cells competent for extravasation. This represents a paradigm of brain endothelial cells influencing the signalling and metastatic competency of breast cancer cells.
Year:
2024
Brain metastases (BrM) develop in 20–40% of patients with advanced cancer. They mainly originate from lung cancer, melanoma, breast cancer, and renal cell carcinoma, and are associated with a poor prognosis. While patients with BrM traditionally lack effective treatment options, immunotherapy is increasingly gaining in importance in this group of patients, with clinical trials in the past decade demonstrating the efficacy and safety of immune checkpoint blockade in BrM originating from specific tumor types, foremost melanoma. The brain is an immune-specialized environment with several unique molecular, cellular, and anatomical features that affect immune responses, including those against tumors. In this review we discuss the potential role that some of these unique characteristics may play in the efficacy of immunotherapy, mainly focusing on the lymphatic drainage in the brain and the role of systemic anti-tumor immunity that develops due to the presence of concurrent extracranial disease in addition to BrM.
Year:
2023
Collaborators (2)
Sibylle Mittnacht
University College London
Valerie Speirs
Professor of Molecular Oncology
University of Aberdeen
Make your next move.
Prepare your application
Review drafts before you send them.